Royal London Asset Management
CHRS icon

Royal London Asset Management’s Coherus Oncology CHRS Stock Holding History

Royal London Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-64,256
Closed -$581K – 658
2018
Q4 		$581K Buy
+64,256
New +$743K 0.01% 649

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal London Asset Management's CHRS Position: Q1 2019 in Review

Royal London Asset Management sold out of Coherus Oncology (CHRS) in Q1 2019, closing a stake of 64,256 shares — an estimated $581K sold.

Royal London Asset Management first reported a position in CHRS in Q4 2018 and held it in 1 quarter. The position peaked at $581K in Q4 2018. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2019.

  • Royal London Asset Management reported no remaining Coherus Oncology position as of Q1 2019 after selling out during the quarter.
  • Royal London Asset Management sold 64,256 Coherus Oncology shares in Q1 2019, an estimated $581K.
  • Royal London Asset Management first reported a position in Coherus Oncology in Q4 2018 and held it in 1 quarter.
  • Royal London Asset Management's Coherus Oncology position peaked at $581K in Q4 2018.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2019.

Based on Royal London Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.